Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 2551 to 2565 of 7684 results

  1. Lisocabtagene maraleucel for treating relapsed or refractory large B-cell lymphomas after first-line chemotherapy when a stem cell transplant is suitable [ID3887]

    In development [GID-TA10778] Expected publication date: TBC

    Technology appraisal guidance
    In development

  2. Erdafitinib for treating metastatic or unresectable FGFR-altered urothelial cancer [ID1333]

    In development [GID-TA10252] Expected publication date: 26 February 2025

    Technology appraisal guidance
    In development

  3. Cabozantinib for treating advanced neuroendocrine tumours that have progressed after systemic treatment ID6474

    In development [GID-TA11613] Expected publication date: TBC

    Technology appraisal guidance
    In development

  4. Artificial intelligence technologies to aid the opportunistic detection of vertebral fragility fractures on radiographic images

    Awaiting development [GID-HTE10059] Expected publication date: 20 August 2025

    Health technology evaluations
    Awaiting development

  5. Isatuximab in combination for untreated multiple myeloma when a stem cell transplant is unsuitable ID3981

    In development [GID-TA10912] Expected publication date: 18 June 2025

    Technology appraisal guidance
    In development

  6. Epcoritamab for treating relapsed or refractory follicular lymphoma ID6338

    In development [GID-TA11385] Expected publication date: TBC

    Technology appraisal guidance
    In development

  7. Obesity: prevention and lifestyle management (QS update)

    In development [GID-QS10184] Expected publication date: TBC

    Quality standard
    In development

  8. Obesity: clinical assessment and management (QS update)

    In development [GID-QS10183] Expected publication date: TBC

    Quality standard
    In development

  9. Cardiovascular risk assessment and lipid modification

    In development [GID-QS10187] Expected publication date: 23 July 2025

    Quality standard
    In development

  10. Elacestrant for treating oestrogen receptor-positive, HER2-negative advanced breast cancer with an ESR1 mutation after at least 1 endocrine treatment [ID6225]

    In development [GID-TA11263] Expected publication date: TBC

    Technology appraisal guidance
    In development

  11. Maralixibat for treating cholestatic pruritus in Alagille syndrome [ID3941]

    In development [GID-TA10832] Expected publication date: 22 January 2025

    Technology appraisal guidance
    In development

  12. 12 SQ-HDM SLIT for treating allergic rhinitis and allergic asthma caused by house dust mites (review of TA834) [ID6280]

    In development [GID-TA11355] Expected publication date: 12 February 2025

    Technology appraisal guidance
    In development

  13. Isatuximab with pomalidomide and dexamethasone for treating relapsed and refractory multiple myeloma [Review of TA658] [ID4067]

    In development [GID-TA10979] Expected publication date: TBC

    Technology appraisal guidance
    In development

  14. Delgocitinib for treating moderate to severe chronic hand eczema ID6408

    In development [GID-TA11506] Expected publication date: TBC

    Technology appraisal guidance
    In development

  15. Pegcetacoplan for treating primary complement 3 glomerulopathy and primary immune-complex membranoproliferative glomerulonephritis in people 12 years and over [ID6489]

    Awaiting development [GID-TA11633] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development